# The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions

> **NCT04012307** · PHASE1 · COMPLETED · sponsor: **Pharmtechnology LLC** · enrollment: 40 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Candesartan Cilexetil 32mg
- **DRUG:** Atacand® PROTECT

## Key facts

- **NCT ID:** NCT04012307
- **Lead sponsor:** Pharmtechnology LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-11
- **Primary completion:** 2019-08-13
- **Final completion:** 2019-08-14
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04012307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04012307, "The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04012307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*